Results 151 to 160 of about 9,592 (241)

Genetic Characterization of Hepatitis C Virus Among People Who Use Crack Cocaine: A Study Conducted on the Brazilian Amazon Coast. [PDF]

Pathogens
Heymbeeck JAA, do Nascimento WL, Freitas MCS, de Sousa Rocha L, Costa FF, de Queiroz JPQ, Simeone D, Martins LC, Machado LFA, Fischer B, Kupek E, Oliveira-Filho AB.   +11 more
europepmc   +1 more source

Combination treatment of Sofosbuvir plus Daclatasvir for 12 weeks in HCV Genotype 3-Infected Bangladeshi patients: Achievment of a Sustained Virological Response [PDF]

Umme Shahera, Nahida Sultana, Munira Jahan, Shahina Tabassum   +3 more
openalex   +1 more source

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir [PDF]

, 2014
Jacques Friborg, Nannan Zhou, Zhou Han, Xiaoyan Yang, Paul Falk, Patricia Méndez, Fiona McPhee   +6 more
openalex   +1 more source

Safety and efficacy of different therapeutic regimens in Egyptian adults with moderate COVID-19 infection (EVEREST): a real-world retrospective study. [PDF]

Sci Rep
Abdel-Salam Elgohary M, Hamza N, Ali A, Zaher Abdel-Rahman R, Thabet Elnagar M, Emam Mohamed M, Seadawy MG, Zenhom Abdelfatah M, Taha NA, Rauof M, El-Bouseary MM.   +10 more
europepmc   +1 more source

Nanoemulsion breakthrough: A New milestone in Oral Daclatasvir Delivery – Screening, formulation, in-vitro evaluation, and in-vivo pharmacokinetic assessment.

Khaled M. Abdel-Haleem, Rehab Nabil Shamma, Nabaweya Abdelaziz Abd El Gawad, Mayar W. Mosharafa   +3 more
openalex   +1 more source

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

, 2015
David R. Nelson, James N. Cooper, Jacob Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley Freilich, Ziad Younes, William R. Harlan, Reem Ghalib, Godson Oguchi, Paul J. Thuluvath, Grisell Ortiz‐Lasanta, Mordechai Rabinovitz, David Bernstein, Michael Bennett, Trevor Hawkins, Natarajan Ravendhran, Aasim Sheikh, Peter Varunok, Kris V. Kowdley, Delphine Hennicken, Fiona McPhee, Khurram Rana, Eric Hughes, on behalf of the ALLY‐3 Study Team   +25 more
openalex   +1 more source

Repurposing antiviral agents against mucormycosis. [PDF]

PLoS One
Khan AA, AlKashef NM, Seleem MN.
europepmc   +1 more source

Specific, highly sensitive and simple spectrofluorimetric method for quantification of daclatasvir in HCV human plasma patients and in tablets dosage form

Open Chemistry, 2019
Ali Ramadan, Elsutohy Mohamed M
doaj   +1 more source

Sensitive RP-HPLC method with fluorimetric detection for concurrent quantification of emtricitabine, Daclatasvir and Ledipasvir in human urine. [PDF]

Sci Rep
Youssef AA, Magdy N, Hussein LA, El-Kosasy AM.   +3 more
europepmc   +1 more source

Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis [PDF]

, 2020
Barclay, Stephen T., Boyle, Alison, Datta, Shouren, Heydtmann, Mathis, Marra, Fiona, Peters, Erica, Priest, Matthew, Ritchie, Trina   +7 more
core   +3 more sources